Pall posted weaker than expected results after the switch to a new ERP system caused “self-inflicted disruption” of supply.
Advancements in single-use equipment are crucial to the development of the biotechnology industry, according to experts at this year’s Interphex.
Pall will buy US instrument maker ForteBio next year in a continuation of efforts to build its biomanufacturing technology offering.
Pall sets up Singapore processing COE
Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
Avacta allies with Pall to serve SE Asian biopharm
Avacta has allied with Pall to offer biopharm manufacturers in Singapore and South Korea tools to assess formulation viability.
Pall ends 2011 on a high as biopharm growth continues
Pall continued the trend seen throughout 2011 by posting double-digit sales growth at its biopharm unit in the fourth quarter.
Biopharma revenues key to Pall’s Q3 gains
Sales to the biopharmaceutical sector drove revenue growth at Pall in third quarter fiscal 2011 and will be key to the firm’s future says CEO.
Biomanufacturing sales key to Pall’s Q4 growth
Pall has ended fiscal 2010 with strong set of sales after recovering pharmaceutical industry demand for bioproduction tech maintained its momentum in Q4
Vaccine demand a friend to Pall in Q1; but sales still fall 5.4%
Continued high demand for vaccine manufacturing technologies saw life sciences emerge as one of the few positives for industrial processing specialist Pall in Q1.
Vaccine growth and single-use systems boost Pall in ‘09
Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Falling biopharma sales hurt Pall’s Q2; but Asia shows promise
Pall CEO Eric Krasnoff says delayed drug industry capital expenditure and moves to conserve inventory in the current global gloom caused life science sales to fall 8 per cent for the second quarter.
Pall hopes to have manufacturing in the bag
Pall Life Sciences has launched its Allegro 3D biocontainers, which have been designed to improve the performance of the company’s large-scale, single use manufacturing systems.
CMOs driving disposable demand
Contract manufacturing organisations (CMOs) have been pinpointed as
a growth driver of single-use biopharmaceutical manufacturing
Pall pushes disposables
As single-use technologies become more and more popular for use in
biopharmaceutical manufacturing, Pall is following market demands
bolstering its product line by adding a number of disposable
products to its portfolio.
Pall continues patent tussle with Entegris
The ongoing intellectual property tussle between Pall and Entegris
continues with Pall claiming Entegris' Impact filter cartridge line
infringes four Pall patents.
Pall Corporation 1Q reveals 16pc sales rise
Filtration system Pall Corporation reported its first quarter
earnings which revealed earnings rose by 16 per cent, propelled by
growth in its industrial and biopharmaceuticals segments.
Pall expands again in chromatography
Filtration and separation company Pall has made another acquisition
in the chromatography sector with the purchase of Euroflow (UK) for
an undisclosed amount.
Pall gets OK for purification process
Pall has been granted European Union and US approval for a
purification process used in biopharmaceutical production that can
reduce the batch testing requirements of manufacturers, as well as
reducing the risk of virus contamination.
Pall life sciences sales held back by lab sector
Filtration and purification specialist Pall has reported a 12.5 per
cent hike in first-quarter sales to $374 million (€310m), with life
sciences putting in a strong showing, up 15.5 per cent to $152
Pall reports sales hike in fourth quarter
Pall has reported a 10 per cent rise in sales to $471 million
(€430m) in the fourth quarter, boosted by currencies and the
recently-acquired FSG operations.